BSE Live
Dec 27, 11:22Prev. Close
5.00
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Oriental Remedies and Herbals (in Rs. Cr.) | Mar 12 | Mar 11 | Mar 10 | Mar 09 | |
| Per Share Ratios | |||||
| Basic EPS (Rs.) | -0.02 | -0.03 | -0.03 | -0.02 | |
| Diluted EPS (Rs.) | -0.02 | -0.03 | -0.03 | -0.02 | |
| Cash EPS (Rs.) | -0.02 | -0.03 | -0.03 | -0.02 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 4.27 | 4.29 | 4.32 | 4.35 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 4.27 | 4.29 | 4.32 | 4.35 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | |
| PBDIT/Share (Rs.) | -0.02 | -0.03 | -0.03 | -0.02 | |
| PBIT/Share (Rs.) | -0.02 | -0.03 | -0.03 | -0.02 | |
| PBT/Share (Rs.) | -0.02 | -0.03 | -0.03 | -0.02 | |
| Net Profit/Share (Rs.) | -0.02 | -0.03 | -0.03 | -0.02 | |
| Profitability Ratios | |||||
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Return on Networth / Equity (%) | -0.47 | -0.67 | -0.58 | -0.48 | |
| Return on Capital Employed (%) | -0.46 | -0.65 | -0.58 | -0.48 | |
| Return on Assets (%) | -0.46 | -0.65 | -0.57 | -0.47 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Liquidity Ratios | |||||
| Current Ratio (X) | 2.01 | 5.26 | 34.88 | 36.78 | |
| Quick Ratio (X) | 2.01 | 5.26 | 34.88 | 36.78 | |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | |||||
| Enterprise Value (Cr.) | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/Net Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | 0.00 | 0.00 | 0.00 | 0.00 |
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth